Key result
Microalbuminuria, detectable in almost 40% of patients with established hypertension, is a marker of renal damage and cardiovascular risk that can be reduced by ACE-inhibitors and ARBs.
Why the study?
Does the detection of microalbuminuria help stratify cardiovascular and renal risk, and do ACE-inhibitors or ARBs reduce it in hypertensive and diabetic patients?
Population
Diabetic patients, essential hypertensive patients, and the general population
Design
Review
Authors
Loading...
Microalbuminuria screening may aid risk stratification in hypertension; leaves open need for dedicated outcome trials on ACEi/ARB reduction.
Does the detection of microalbuminuria help stratify cardiovascular and renal risk, and do ACE-inhibitors or ARBs reduce it in hypertensive and diabetic patients?
Microalbuminuria is a simple and reproducible marker for stratifying cardiovascular and renal risk in hypertensive patients, guiding the use of targeted therapies like ACE-inhibitors and ARBs.
Segura et al. (2004) conducted a review in Essential hypertension and diabetes mellitus. Microalbuminuria was evaluated. Microalbuminuria, detectable in almost 40% of patients with established hypertension, is a marker of renal damage and cardiovascular risk that can be reduced by ACE-inhibitors and ARBs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: